NUVL - Nuvalent, Inc.
100.22
-1.070 -1.068%
Share volume: 475,751
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$101.29
-1.07
-0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-08-2024 | 11-12-2024 | 02-27-2025 | 05-08-2025 | 10-30-2025 | 02-26-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 52.588 M | 65.150 M | 76.331 M | 86.299 M | 94.812 M | 112.696 M | 102.228 M | |
| Selling general and admin | 13.954 M | 15.984 M | 15.780 M | 16.876 M | 20.394 M | 28.853 M | 34.432 M | |
| Research and development | 38.634 M | 49.166 M | 60.551 M | 69.423 M | 74.418 M | 83.843 M | 67.796 M | |
| Total expenses | 52.588 M | 65.150 M | 76.331 M | 86.299 M | 94.812 M | 112.696 M | 102.228 M | |
| 23.89% | 17.16% | 13.06% | 9.86% | 18.86% | -9.29% | |||
| Operating income | -52.588 M | -65.150 M | -76.331 M | -86.299 M | -94.812 M | -112.696 M | -102.228 M | |
| Ebit | -52.588 M | -65.150 M | -76.331 M | -86.299 M | -94.812 M | -112.696 M | -102.228 M | |
| Pretax income | -44.099 M | -56.996 M | -84.305 M | -74.592 M | -84.425 M | -122.305 M | -118.554 M | |
| 29.25% | 47.91% | -11.52% | 13.18% | 44.87% | -3.07% | |||
| Income tax | 383.000 K | 170.000 K | 40.000 K | 171.000 K | 157.000 K | 132.000 K | 151.000 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -44.482 M | -57.166 M | -84.345 M | -74.763 M | -84.582 M | -122.437 M | -118.705 M | |
| -28.51% | -47.54% | 11.36% | -13.13% | -44.76% | 3.05% |